MedTrace Logo

A Phase 1 Clinical Trial DHP2306R1 and DHP2306R2 in Healthy Adult Volunteers

NCT06395155 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2024-07-25

No results posted yet for this study

Summary

This phase 1 study is to evaluate the safety and pharmacokinetic drug interactions of DHP2306R1 and DHP2306R2 when administered alone and in combination in healthy conditions.

Participants will be taken DHP2306R1 and DHP2306R2 alone or combination for 3 period, randomized in six-sequence.

Conditions

Interventions

DRUG

DHP2306R1

100mg per capsule, BID

DRUG

DHP2306R2

75mg per Tab, BID

Sponsors & Collaborators

  • Daehwa Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Min Kyu Park · Chungbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-26
Primary Completion
2023-12-07
Completion
2023-12-07

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06395155 on ClinicalTrials.gov